Table 1.
Baseline characteristics of the cohort (Total n=318).
| Characteristic | Total (n=318) Number (%) | CONV (n=88) Number (%) | TCD (n=230) Number (%) |
|---|---|---|---|
| Age | |||
| Mean (sd) years | 53.8 (13.0) | 53.4 (12.4) | 53.9 (13.2) |
| Median (IQR) years | 56.2 (46.5–64.6) | 54.7 (47.3–63.3) | 56.9 (45.6–64.8) |
| Sex | |||
| Female | 138 (43.4) | 31 (35.2) | 107 (46.5) |
| Male | 180 (56.6) | 57 (64.8) | 123 (53.5) |
| Recipient (R) and Donor (D) CMV serostatus | |||
| R+/D+ | 108 (34.0) | 31 (35.2) | 77 (33.5) |
| R+/D− | 79 (24.8) | 15 (17.0) | 64 (27.8) |
| R−/D+ | 40 (12.6) | 15 (17.0) | 25 (10.9) |
| R−/D− | 91 (28.6) | 27 (30.7) | 64 (27.8) |
| Underlying disease | |||
| Acute lymphoblastic leukemia | 30 (9.4) | 0 | 30 (13.0) |
| Acute myeloid leukemia | 159 (50.0) | 32 (36.4) | 127 (55.2) |
| Myelodysplastic syndrome | 78 (24.5) | 5 (5.7) | 73 (31.7) |
| Chronic lymphocytic leukemia | 12 (3.8) | 12 (13.6) | 0 |
| Hodgkin’s Disease | 12 (3.8) | 12 (13.6) | 0 |
| Non-Hodgkin’s Lymphoma | 27 (8.5) | 27 (30.7) | 0 |
| Donor type | |||
| Matched related | 114 (35.8) | 39 (44.3) | 75 (32.6) |
| Matched unrelated | 149 (46.9) | 41 (46.6) | 108 (47.0) |
| Mismatched related | 3 (0.9) | 1 (1.1) | 2 (0.9) |
| Mismatched unrelated | 52 (16.4) | 7 (8.0) | 45 (19.6) |
| Conditioning regimen | |||
| Myeloablative | 230 (72.3) | 0 | 230 (100.0) |
| Busulfan/Melphalan/Fludarabine | 153 (48.1) | 0 | 153 (66.5) |
| Clofarabine/Thio-TEPA/Melphalan | 13 (4.1) | 0 | 13 (5.7) |
| TBI/Thio-TEPA/Cyclophosphamide or fludarabine | 64 (20.1) | 0 | 64 (27.8) |
| Reduced intensity | 88 (27.7) | 88 (100.0) | 0 |
| Fludarabine/Busulfan* | 67 (21.1) | 67 (76.1) | 0 |
| Melphalan | 1 (0.3) | 1 (1.1) | 0 |
| TBI/Cyclophosphamide/Fludarabine/Thio- TEPA/ | 20 (6.3) | 20 (22.7) | 0 |
*
Three patients also received Rituximab.